BRPI0914978A2 - sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos - Google Patents

sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos

Info

Publication number
BRPI0914978A2
BRPI0914978A2 BRPI0914978A BRPI0914978A BRPI0914978A2 BR PI0914978 A2 BRPI0914978 A2 BR PI0914978A2 BR PI0914978 A BRPI0914978 A BR PI0914978A BR PI0914978 A BRPI0914978 A BR PI0914978A BR PI0914978 A2 BRPI0914978 A2 BR PI0914978A2
Authority
BR
Brazil
Prior art keywords
oxadiazolone
pharmaceuticals
reinforced
core
processes
Prior art date
Application number
BRPI0914978A
Other languages
English (en)
Inventor
Eugen Falk
Hans Matter
Maike Glien
Matthias Urmann
Stefanie Keil
Wolfgang Wendler
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of BRPI0914978A2 publication Critical patent/BRPI0914978A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BRPI0914978A 2008-06-09 2009-05-22 sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos BRPI0914978A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08290572 2008-06-09
PCT/EP2009/003648 WO2009149820A1 (en) 2008-06-09 2009-05-22 Annelated n-heterocyclic sulfonamides with oxadiazolone headgroup, processes for their preparation and their use as pharmaceuticals

Publications (1)

Publication Number Publication Date
BRPI0914978A2 true BRPI0914978A2 (pt) 2015-10-27

Family

ID=40219356

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0914978A BRPI0914978A2 (pt) 2008-06-09 2009-05-22 sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos

Country Status (19)

Country Link
US (2) US8329725B2 (pt)
EP (1) EP2288604B1 (pt)
JP (1) JP2011523664A (pt)
KR (1) KR20110023855A (pt)
CN (1) CN102056921A (pt)
AR (1) AR072013A1 (pt)
AU (1) AU2009256982A1 (pt)
BR (1) BRPI0914978A2 (pt)
CA (1) CA2727373A1 (pt)
CL (1) CL2009001365A1 (pt)
IL (1) IL209805A0 (pt)
MA (1) MA32323B1 (pt)
MX (1) MX2010013264A (pt)
NZ (1) NZ589694A (pt)
RU (1) RU2010154279A (pt)
TW (1) TW201011012A (pt)
UY (1) UY31872A (pt)
WO (1) WO2009149820A1 (pt)
ZA (1) ZA201007679B (pt)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029685A1 (en) * 2006-10-25 2010-02-04 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP6063870B2 (ja) * 2010-11-08 2017-01-18 ライセラ・コーポレイション RORγ活性の阻害用のN−スルホニル化テトラヒドロキノリンおよび関連二環化合物および病気の治療
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
RU2014149136A (ru) 2012-05-08 2016-07-10 Мерк Шарп И Доум Корп. ТЕТРАГИДРОНАФТИРИДИНОВЫЕ И РОДСТВЕННЫЕ БИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ ДЛЯ ИНГИБИРОВАНИЯ RORγ АКТИВНОСТИ И ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ
WO2013169864A2 (en) 2012-05-08 2013-11-14 Lycera Corporation TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE
US9663502B2 (en) 2013-12-20 2017-05-30 Lycera Corporation 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
US9809561B2 (en) 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
US9783511B2 (en) 2013-12-20 2017-10-10 Lycera Corporation Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
MX2016010998A (es) 2014-02-27 2017-03-31 Lycera Corp Terapia celular adoptiva que usa un agonista de receptor huérfano gamma relacionado con receptor de ácido retinoico y métodos terapéuticos relacionados.
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
CA2975997A1 (en) 2015-02-11 2016-08-18 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as rorgammat inhibitors and uses thereof
CA2982847A1 (en) 2015-05-05 2016-11-10 Lycera Corporation Dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
HK1253734A1 (zh) 2015-06-11 2019-06-28 The Regents Of The University Of Michigan 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1,4]恶嗪磺酰胺和相关化合物
CA3002850A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. Substituted indazole compounds as rorgammat inhibitors and uses thereof
JP2018531958A (ja) 2015-10-27 2018-11-01 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. RORγT阻害薬としてのヘテロアリール置換安息香酸及びその使用
AU2016344111A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Substituted bicyclic pyrazole compounds as RORgammaT inhibitors and uses thereof
CN110407721A (zh) * 2019-08-13 2019-11-05 上海毕得医药科技有限公司 一种4-氰基-3-(三氟甲基)苯-1-磺酰氯的合成方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1345890A1 (en) * 2000-11-17 2003-09-24 Novo Nordisk A/S Glucagon antagonists/inverse agonists
DE10222034A1 (de) 2002-05-17 2003-11-27 Bayer Ag Tetrahydroisochinolin-Derivate
DE10229777A1 (de) 2002-07-03 2004-01-29 Bayer Ag Indolin-Phenylsulfonamid-Derivate
CA2521175A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
DE10335450A1 (de) 2003-08-02 2005-02-17 Bayer Ag Indolin-Sulfanilsäureamide
DE10335449A1 (de) 2003-08-02 2005-02-17 Bayer Healthcare Ag Bicyclische Indolinsulfonamid-Derivate
KR20060134191A (ko) 2004-04-01 2006-12-27 아벤티스 파마슈티칼스 인크. 미엘린 탈락 질환을 치료하기 위한 ppr 델타 효능제의용도
DE602004004631D1 (de) 2004-04-01 2007-03-22 Sanofi Aventis Deutschland Oxadiazolone, Verfahren zu ihrer Herstellung sowie ihre Verwendung als Pharmazeutika
US7601716B2 (en) 2006-05-01 2009-10-13 Cephalon, Inc. Pyridopyrazines and derivatives thereof as ALK and c-Met inhibitors
EP1932843A1 (en) * 2006-12-14 2008-06-18 sanofi-aventis Sulfonyl-phenyl-2H-(1,2,4) oxadiazole-5-one derivatives, processes for their preparation and their use as pharmaceuticals
WO2010007972A1 (ja) * 2008-07-14 2010-01-21 参天製薬株式会社 カルバモイル基、ウレイド基及び置換オキシ基を有する新規インドール誘導体
KR20110111403A (ko) * 2009-02-05 2011-10-11 고쿠리츠 다이가쿠 호진 교토 다이가쿠 인돌린 유도체
MX2012013196A (es) * 2010-05-12 2013-03-22 Abbvie Inc Inhibidores de pirrolopiridina y pirrolopirimidina de cinasas.

Also Published As

Publication number Publication date
US8329725B2 (en) 2012-12-11
MX2010013264A (es) 2011-02-25
ZA201007679B (en) 2011-07-27
US20110207738A1 (en) 2011-08-25
TW201011012A (en) 2010-03-16
US8946212B2 (en) 2015-02-03
RU2010154279A (ru) 2012-07-20
US20120122853A1 (en) 2012-05-17
CA2727373A1 (en) 2009-12-17
CN102056921A (zh) 2011-05-11
AU2009256982A1 (en) 2009-12-17
EP2288604B1 (en) 2014-01-08
MA32323B1 (fr) 2011-05-02
IL209805A0 (en) 2011-02-28
JP2011523664A (ja) 2011-08-18
EP2288604A1 (en) 2011-03-02
AR072013A1 (es) 2010-07-28
WO2009149820A1 (en) 2009-12-17
NZ589694A (en) 2012-05-25
KR20110023855A (ko) 2011-03-08
CL2009001365A1 (es) 2010-11-05
UY31872A (es) 2010-01-29

Similar Documents

Publication Publication Date Title
BRPI0914978A2 (pt) sulfonamidas n-heterocíclicas reforçadas com grupo principal de oxadiazolona, processos para sua preparação e seu uso como farmacêuticos
BRPI0821915A2 (pt) Piridil-n-(1,3,4)-tiadiazol-2-il-benzeno sulfonamidas cíclicas, processos para sua preparação e seu uso como produtos farmacêuticos
BRPI1011043A2 (pt) compostos de fenilureias e fenilamidas substituídas como ligantes de receptor de vaniloide, sua composição farmacêutica, seu uso e seu processo de preparação.
BRPI0912356A2 (pt) compostos moduladores de sirtuína, composição farmacêutica compreendendo os mesmos e seu uso
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BR112013023015A2 (pt) conjungado de amatoxina e seu uso, composição farmacêutica e seu uso, molécula de conjugação de amatoxina, método para a síntese de um conjungado de amatoxina.
BR112012001257A2 (pt) complexo catalítico para reações de metátese de olefinas, processo para sua preparação e uso do mesmo
BR112013016772A2 (pt) composto, uso do composto, composição farmacêutica, oligonucleotídeo e conjugado
BRPI1014583A2 (pt) sulfonamidas heterocíclicos, composições farmacêuticas e usos do mesmo.
BRPI1007018A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
BR112012000387A2 (pt) placa de osteotomia , placa condutora e método para seu uso
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
BRPI1014464A2 (pt) 4-ciano-3-benzoilamino-n-fenil-benzamidas para uso no controle de pragas
BRPI0918502A2 (pt) aminoindanos substituídos e análogos dos mesmos, e o uso farmacêutico dos mesmos
BR112013020352A2 (pt) composto, composição farmacêutica, uso de um composto e método para tratar doença ou condição mediana por rorgamat num indivíduo
BR112014030275A2 (pt) método para obter um material sólido com base em um polímero, material sólido, e, uso de material sólido.
BRPI0919810A2 (pt) compostos heterocíclicos contendo nitrogênio, sua preparação e seu uso como medicamentos antibacterianos
BRPI1013050A2 (pt) aparelho e mistura para misturar substâncias, e, microchip.
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BRPI0818459A2 (pt) Composição farmacêutica adequada para uso oftálmico.
BRPI1009757A2 (pt) composto, composição farmacêutica, e , uso de um composto.
BRPI0919807A2 (pt) compostos nitrogenosos heterocíclicos , sua preparação e seu uso como medicamentos antibacterianos
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
BRPI1014125A2 (pt) composto, composição farmacêutica, e, uso de um composto.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]